
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio is showing promising signs of demand for their clinical trials, with the completion of enrollment in the pivotal Phase 3 trial for their flagship drug candidate, buntanetap. Additionally, the company has a potential NDA submission in the works for the disease progression component of their product. With positive Phase 3 trial results, fast track designation from the FDA, and potential collaboration revenue, Annovis Bio has strong potential for growth in the future.
Bears say
Annovis Bio is facing major risks to their stock, including a potential lack of FDA acceptance and eventual unsuccessful launches or commercial performance. They also have a modest cash runway and are focused on difficult-to-treat diseases, which could lead to trial failures due to lack of efficacy or safety. Additionally, increased competition and pricing pressures could negatively impact their financial performance in the future.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares